Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Devine, Steven M  [Clear All Filters]
2014
Nash, R.A., Hutton, G.J., Racke, M.K., Popat, U., Devine, S.M., Griffith, L.M., Muraro, P.A., Openshaw, H., Sayre, P.H., Stüve, O., et al. (2014). High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS): A 3-Year Interim Report.Jama Neurol.
Dubovsky, J.A., Flynn, R., Du, J., Harrington, B.K., Zhong, Y., Kaffenberger, B., Yang, C., Towns, W.H., Lehman, A., Johnson, A.J., et al. (2014). Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.J Clin Invest.
Salem, G., Ruppert, A.S., Elder, P., Hofmeister, C.C., Benson, D.M., Penza, S., Andritsos, L., Klisovic, R., Vasu, S., Blum, W., et al. (2014). Lower Dose of Antithymocyte Globulin (ATG) does not increase Graft-vs-Host Disease (GVHD) in Patients Undergoing Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (allo HSCT).Leuk Lymphoma1-20.
Lund, T.C., Cathey, S.S., Miller, W.P., Eapen, M., Andreansky, M., Dvorak, C.C., Davis, J.H., Dalal, J.D., Devine, S.M., Eames, G.M., et al. (2014). Outcomes after Hematopoietic Stem Cell Transplant for Children with I-Cell Disease.Biol Blood Marrow Transplant.
Maziarz, R.T., Devos, T., Bachier, C.R., Goldstein, S.C., Leis, J.F., Devine, S.M., Meyers, G., Gajewski, J.L., Maertens, J., Deans, R.J., et al. (2014). Single and Multiple Dose MultiStem® (Multi-Potent Adult Progenitor Cell) Therapy Prophylaxis of Acute GVHD in Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Phase I Trial.Biol Blood Marrow Transplant.